Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260783 | 1.00 | ALDH1A1 (0.45) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL9527329 | 0.86 | ALDH1A1 (0.56) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL17119223 | 0.82 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9530922 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2826555 | 0.76 | ALDH1A1 (0.48) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL9051575 | 0.76 | ALDH1A1 (0.75) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3198101 | 0.75 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL17343101 | 0.74 | ALDH1A1 (0.46) | ALDH1A1POLBTSHRCASP1BRCA1 | |
| SCHEMBL9526176 | 0.74 | ALDH1A1 (0.46) | ALDH1A1POLBTSHRCASP1BRCA1 | |
| SCHEMBL10469633 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | ALDH1A1 1383/4885POLB 4051/4885SMN1; SMN2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.